BVX - Bovie Medical Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
7.31
+0.10 (+1.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.21
Open7.19
Bid0.00 x 800
Ask7.75 x 1400
Day's Range7.02 - 7.31
52 Week Range2.28 - 7.62
Volume470,216
Avg. Volume198,495
Market Cap242.718M
Beta-1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.11
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.88
Trade prices are not sourced from all markets
  • Business Wire11 days ago

    Bovie Medical Corporation to Present at the Sidoti & Company Fall 2018 Investor Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the Sidoti & Company Fall 2018 Investor Conference at the Grand Hyatt in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/.

  • Business Wire18 days ago

    Bovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today updated financial guidance expectations for the twelve months ending December 31, 2018. The Company is introducing fiscal year 2018 financial guidance on a continuing operations basis as adjusted, which reflects the consummation of the Core segment sale transaction which closed on August 30, 2018. Total revenue from continuing operations in the range of $15.2 million to $15.6 million, representing growth of 49% to 53% year-over-year, compared to total revenue from continuing operations of $10.2 million in fiscal year 2017.

  • Business Wire23 days ago

    Bovie Medical Corporation Announces Completion of “Core” Business Segment Sale to Symmetry Surgical, Inc. for Total Cash Consideration of $97 Million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that it has completed the previously announced divestiture and sale of the Core business segment and the Bovie® brand to Symmetry Surgical, Inc. for gross proceeds of $97 million in cash. Bovie Medical shareholders voted to approve the divestiture and sale transaction at an annual meeting of shareholders held on August 30, 2018.

  • Associated Press2 months ago

    Bovie: 2Q Earnings Snapshot

    On a per-share basis, the Clearwater, Florida-based company said it had a loss of 1 cent. The medical device maker posted revenue of $11.5 million in the period. In the final minutes of trading on Wednesday, ...

  • Business Wire2 months ago

    Bovie Medical Corporation Reports Second Quarter 2018 Financial Results

    Advanced Energy Sales of $3.1 million in Q2, up 72% year-over-year

  • Business Wire2 months ago

    Bovie Medical Corporation to Release Second Quarter of Fiscal Year 2018 Financial Results on August 1, 2018

    Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the second quarter of fiscal year 2018 will be released after the market closes on Wednesday, August 1. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • MarketWatch2 months ago

    Bovie Medical's stock jumps after deal to sell core business

    Bovie Medical Corp.'s stock (bvx) soared 10% toward a 20-month high in premarket trade Monday, after the medical device company said it reached a deal to sell its "core" business and the Bovie brand for $97 million in cash to Symmetry Surgical Inc. As part of the deal, which is expected to close in the third quarter of 2018, Bovie said it will enter into transition services, patent licensing, disposables supply and generator manufacturing and supply agreements with Symmetry. "This is a milestone moment for the Company, one that creates significant value for our shareholders by significantly enhancing our balance sheet with the addition of more than $70 million in estimated net cash proceeds after taxes and transaction related expenses and allowing us to further focus the organization on our strategic objective of commercializing our J-Plasma/Renuvion technology in the cosmetic surgery market," said Chief Executive Charlie Goodwin.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that the Company has entered into a definitive agreement with Specialty Surgical Instrumentation Inc., a subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company will divest and sell the Core business segment and the Bovie® brand to Symmetry for gross proceeds of $97 million in cash. The asset purchase agreement was approved by the Company’s Board of Directors and is subject to customary closing conditions – including approval by the Company’s stockholders – and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced preliminary revenue results for the second quarter of fiscal year 2018.

  • Business Wire4 months ago

    Bovie Medical Corporation to Participate in the JMP Securities 2018 Life Science Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the JMP Securities 2018 Life Science Conference at the St. Regis New York in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • ACCESSWIRE4 months ago

    Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.

  • ACCESSWIRE4 months ago

    Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...

  • Associated Press4 months ago

    Bovie: 1Q Earnings Snapshot

    The Clearwater, Florida-based company said it had a loss of 3 cents per share. The medical device maker posted revenue of $9.9 million in the period. Bovie expects full-year revenue in the range of $41 ...

  • Business Wire4 months ago

    Bovie Medical Corporation Reports First Quarter 2018 Financial Results; Reaffirms Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March 31, 2018.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Completion of Enrollment in J-Plasma®/RenuvionTM Dermal Resurfacing Study

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the completion of enrollment for the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing. “We are excited to announce that today we have enrolled the final patient in our dermal skin resurfacing study, which represents another important development in our strategy to build clinical support for our Renuvion technology and expand its clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.

  • ACCESSWIRE4 months ago

    Bovie Medical Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Bovie Medical Corporation (NYSE American: BVX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern ...

  • Business Wire5 months ago

    Bovie Medical Corporation Announces Appointment of Diane I. Duncan, M.D., FACS to Medical Advisory Board

    Bovie Medical Corporation (BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Diane I. Duncan, M.D., FACS to the Company’s Medical Advisory Board. “Dr. Duncan joins our Medical Advisory Board with over 30 years of experience in private practice as a plastic surgeon,” said Charlie Goodwin, Chief Executive Officer.

  • Business Wire5 months ago

    Bovie Medical Corporation to Release First Quarter of Fiscal Year 2018 Financial Results on May 14, 2018

    Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the first quarter of fiscal year 2018 will be released after the market closes on Monday, May 14.

  • Business Wire6 months ago

    Bovie Medical Corporation Announces Launch of Renuvion™: A New Brand Dedicated to the Cosmetic Surgery Market

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the launch of Renuvion™, a new brand that is dedicated to the cosmetic surgery market.

  • Business Wire6 months ago

    Bovie Medical Corporation Announces Appointment of Scott R. Sanders as Director of Clinical Education and Market Development

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the appointment of Scott R.

  • Associated Press6 months ago

    Bovie reports 4Q loss

    On a per-share basis, the Purchase, New York-based company said it had a loss of 3 cents. The medical device maker posted revenue of $11.3 million in the period. For the year, the company reported that ...

  • Business Wire6 months ago

    Bovie Medical Corporation Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today reported financial results for its fourth quarter and full year ended December 31, 2017.

  • Business Wire6 months ago

    Bovie Medical Corporation Announces Appointment of Craig A. Swandal to Board of Directors

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the appointment of Craig A.

  • ACCESSWIRE6 months ago

    Bovie Medical Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Bovie Medical Corporation (Nyse American: BVX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 4:30 PM ...